PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $63,234 | $33,685 |
| Short-term investments | 431,011 | 297,502 |
| Accounts receivable | — | 1,983 |
| Tax credit receivable | — | 83 |
| Prepaid expenses and other current assets (Note 5) | 11,257 | 7,058 |
| Total current assets | 505,502 | 340,311 |
| Property and equipment, net | 3,567 | 4,486 |
| Operating lease right-of-use assets | 1,211 | 5,422 |
| Restricted cash | 1,482 | — |
| Other non-current assets | 392 | 394 |
| Total assets | $512,154 | $350,613 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $4,531 | $1,580 |
| Accrued research and development | 12,456 | 11,218 |
| Accrued liabilities (Note 6) | 10,219 | 8,658 |
| Lease liabilities, current | 1,318 | 2,457 |
| Total current liabilities | 28,524 | 23,913 |
| Lease liabilities, non-current | — | 3,429 |
| Long-term debt (Note 7) | 10,054 | 9,929 |
| Total liabilities | 38,578 | 37,271 |
| Commitments and Contingencies (Note 13) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2023 and 2022, none issued or outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2023 and 2022; and 59,921,002 and 48,941,254 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively; | 6 | 5 |
| Additional paid-in capital | 972,973 | 653,707 |
| Accumulated deficit | (499,748) | (338,412) |
| Accumulated other comprehensive gain (loss) | 345 | (1,958) |
| Total stockholders’ equity | 473,576 | 313,342 |
| Total liabilities and stockholders’ equity | $512,154 | $350,613 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.